Multiple sclerosis (MS) and infectious mononucleosis share certain epidemiological features; that is, both diseases occur preferentially in adolescents and young adults in the middle and upper class segments of economically advanced nations, whereas they are rare in underdeveloped countries. The reason for this epidemiological pattern of infectious mononucleosis has become clear with the identification of the Epstein-Barr virus as its cause (cf. 2). Under low socio-economic conditions, primary Epstein-Barr virus infections occur commonly early in life when they remain either silent or cause such mild signs and symptoms that the nature of the disease remains unidentified, yet they engender a life-long immunity. Under high socio-economic conditions, primary Epstein-Barr virus infections are often delayed to adolescence or early adulthood when more severe disease, i.e., infectious mononucleosis, is likely to ensue. It is conceivable that a similar situation obtains with respect to MS. Its causative agent might be more common than presently anticipated, it might cause usually no or only mild illnesses in childhood, and MS might be an unusual consequence of infections at a later age. Whereas this hypothesis cannot be tested properly until the etiological agent of MS has been identified, it offers an additional parameter in evaluating the relation of candidate viruses to MS.
There exists now a candidate which was first described by Carp and his associates (1) and confirmatory evidence has been presented by this laboratory (5) . Brain homogenates and sera from MS patients contain at a high frequency an agent which induces a transitory depression of circulating polymorphonuclear leukocytes (PMN) in mice, rats, hamsters, and guinea pigs. This evidently MS-associated agent (MSAA) appears to be a small virus, since it is sedimentable at 105,000 x g but not at 50,000 x g, passes through 50-nm but not 25-nm membrane filters (Millipore Corp.), replicates to high titers in the central nervous tissue ofinoculated animals, and is transmissible serially from animal to animal by passage of brain homogenates in high dilutions. Various observations seemed to preclude that the agent represents an indigenous virus of experimental animals activated by injection of MS materials (1, 5) . Furthermore, as will be shown in this report, antibodies which neutralize MSAA are found at considerable frequencies in sera from certain groups of donors.
MATERIALS AND METHODS MSAA. Various MS brain homogenates, MS sera, or mouse passage brain suspensions prepared and titrated as previously described (5) served as sources of MSAA. The mouse passage brain homogenates, used most extensively, induced PMN depressions when diluted as high as 10-8 or 10-9. For neutralization tests, a 10-6dilution of the mouse brain suspensions was employed, i.e., between 102 and 103 PMN depressing units, which usually caused a PMN reduction ofclose to 50%. If less, the P values are given in the tables.
Sera. These included sera from MS patients and their relatives and nursing personnel collected and stored as described (5) . In addition, sera were selected from various available collections maintained at -20 C, i.e., sera from patients with Hodgkin's disease and appropriate controls (3), provided by Henry S. Kaplan, Stanford University Medical Center; acute and convalescent sera from patients with unidentifiable, presumably viral, infections of the central nervous system, supplied by Edwin H. Lennette, California State Health Department; and sera from donors in the West Nile District of Uganda, ranging in age from 1 to >70 years, which had been collected for Epstein-Barr virus-related seroepidemiological studies (4) .
MSAA neutralization tests. All sera were inactivated at 56 C for 30 min prior to use. In qualitative tests, they were diluted 5-or 10-fold, and, for titrations, serial 10-fold dilutions were employed. The serum dilutions were mixed with equal volumes of MSAA-containing materials diluted to yield between 102 and 103 PMN depressing units per dose. The mixtures were incubated at 4 C for 1 h before injection of 0.2 ml by the intraperitoneal route into groups of three to six mice each. Groups of mice injected with (i) the dose of MSAA mixed with phosphate-buffered saline (PBS) (MSAA control), (ii) the serum dilution mixed with PBS (serum control), and (iii) PBS only (PMN base line control) served as controls. Blood smears were prepared 6 to 20 days later, and the percentages of PMNs were determined as described (5 figure, and multiplication of the result by 100. An NI value of -90 is considered to denote definite, and an NI of 50 to 89 denotes probable, neutralizing activity.
Preparation of IgG fractions. Immunoglobulin G (IgG) fractions were separated from individual or pooled human sera on diethylaminoethyl-cellulose columns according to the method of Levy and Sober (6) .
Dissociation of antigen-antibody complexes. Individual or pooled sera (1.5 ml) from MS patients were centrifuged at 105,000 x g for 1 h. The pellets were rinsed twice with PBS and resuspended in 1.5 ml of glycine-hydrochloride buffer of pH 2.6 by vigorous pipetting. After incubation in an ice bath with intermittent agitation for 1 h the preparations were subjected to 105,000 x g for 30 min and the pellets were discarded. The supernatants, after adjustment of the pH to 6.2 by addition of 1 M K2HPO4, were dialyzed against PBS and tested for MSAA neutralizing activity. The final preparations were shown by acrylamide electrophoresis to yield two bands corresponding to IgG and albumin.
RESULTS
As discussed previously (5), the induction of PMN depressions by MSAA in experimental animals is easily influenced by various factors which affect the distribution of peripheral leukocytes. The same problems are encountered obviously also in the MSAA neutralization test, which is based on the prevention of PMN depressions. This test is further complicated by the simultaneous presence of MSAA and MSAA neutralizing activity in sera from many patients with MS, as will be documented later. Yet, satisfactory results were obtained in the majority of experiments.
Qualitative and quantitative neutralization tests. In an initial test, commercial human gamma globulin preparations were found to have no MSAA neutralizing activity. This result indicated that the incidence of antibodies to this agent among healthy American donors would certainly be low. However, neutralizing activity was found in a considerable proportion of sera from nursing personnel and relatives of MS patients. were negative, 48% had NIs of .50, and 26% had NIs of '90. Only one of the total of 37 sera from Hodgkin's disease patients and a corresponding control group neutralized MSAA (2.7%), a serum from a medical technician, and the rest were negative, as were all the 22 convalescent sera from patients with unidentifiable, presumably viral, encephalitis. In contrast to the American control patients or healthy individuals, 37% of the 68 sera from East African donors showed NI values of _50 and 16% of .90, whereas 56% were clearly negative. When subdivided according to age ranges, the incidence of strong neutralizing activity (NI _90) increased stepwise from 23% among African children 1 to 15 years old to 67% among donors over 50 years of age.
The titers of 30 positive sera were determined, using 10-fold dilution steps. (Fig. 1) . In further tests, the IgG fractions were separated from five positive sera (three used as a pool) and examined together with samples of the original sera. The two examples given in Table 3 show that the neutralizing activity was recovered in the IgG fraction, with a slight loss in the case of serum GE-5N (nursing staff) and possibly a gain in the case of the serum from MS patient GE-61. It is thus likely that the neutralization of MSAA is due to an antibody.
Neutralizing activity of cerebrospinal fluids. As reported (5), none of the spinal fluids examined thus far, whether from patients with MS or other neurological disorders, induced PMN depressions in mice. Several of these were tested for MSAA neutralizing activity ( Table   4 ). The four spinal fluids from MS patients gave strongly positive results (NI 84 to 100). The sera from these patients all had induced significant PMN depressions, two had also strong neutralizing activity (see later), one had none, and the fourth could not be tested, since it had been exhausted. The spinal fluids from the two control patients were clearly devoid of neutralizing activity.
Evidence for antigen-antibody complexes in MS sera. Observations recorded previously (5) at low pH. The final preparation was shown to contain IgG and completely neutralized (NI 100) a dose of MSAA, which in this test equaled or exceeded 1,000 U.
DISCUSSION
The above experiments have shown that a considerable proportion of human sera from certain categories of donors has the capacity to neutralize MSAA. This observation supports the earlier conclusion (1, 5) that MSAA is present in specimens from MS patients and not picked up from the inoculated animals. This interpretation does not necessarily denote that MSAA is primarily a human virus; it could still be an animal virus, which incidentally infects humans on occasion.
Some sera could be diluted as much as 100-or 1,000-fold and still reduce or completely prevent the PMN depressions induced by MSAA in mice. The neutralizing activity was found to be associated with the IgG fraction of the sera and thus appears to be due to an antibody. Such antibodies were demonstrable in sera and, most importantly, also in cerebrospinal fluids from MS patients. They were found, in addition, at considerable frequency in sera from relatives and nursing personnel of MS patients. They seem to be rare in sera from American donors without known contact with MS patients, whether healthy or suffering from other neurological or nonneurological diseases, but they were observed in about one-third of the sera collected from donors living in an underdeveloped country under poor hygienic conditions. Limited as the available data are, they appear to agree with the considerations presented in the introduction to this report; that is, MS might be an unusual manifestation of an infection by a virus which is more widely disseminated than indicated by the actual cases of disease and might normally cause no or only mild transitory illnesses of an as yet unknown type. The seroepidemiological approach certainly deserves further exploration, but preferably with a more convenient and dependable test procedure than the present MSAA neutralization test.
The assay, which depends on the prevention of PMN depressions in mice by MSAA, is subject to many variables which affect the distribution of peripheral leukocytes (cf. 5). Depending on the dose of MSAA and the strain of mice, PMN (5) . Whereas this test of significance was judged most appropriate for the variability of the PMN depression assay, it is also the most severe test. In view of these considerations, it is difficult to decide what degree of reversal of PMN depressions, that is, which NI value, should be taken as valid evidence of neutralizing activity in a serum. When the NI values decline successively on progressive dilution of a test serum from 100 to an intermediate figure to zero, an NI of 50 might well be taken as end point. This value is not as readily acceptable in qualitative neutralization tests with merely 5-or 10-fold-diluted sera since conceivably nonspecific factors might enter or, as in the case of MS sera, antigen-antibody complexes might affect the results.
The simultaneous presence of MSAA and MSAA neutralizing antibodies in MS sera was suggested by the observations (5) that the degree of PMN depressions induced by some MS sera increased after clarifications at 50,000 x g, after filtration through 100-or 50-nm membrane filters (Millipore Corp.), or with progressive dilution before the end point of activity was reached. As shown in this report, MS sera, which before inactivation had the capacity to induce PMN depressions of high or borderline significance, might reveal considerable MSAA neutralizing activity after heat inactivation. Again, "prozones" were observed, in that some sera which were titrated yielded lower NI values 1:5 or 1:10 dilutions than at 5-or 10-fold higher dilutions. It is evident that accurate evaluation of the relative representations of MSAA or MSAA neutralizing antibodies in given sera requires titration of both. The fact remains that both activities were detected in many MS sera and that antigen-antibody complexes were sedimentable from such sera, which yielded neutralizing antibodies on dissociation at a low pH. These observations appear to be comparable to results obtained with hepatitis B (HB) patients, who may show either HB antigen or HB antibodies in their sera in excess over the corresponding antigen-antibody complexes (cf. 7). The data are as yet far too limited to attempt a correlation of the results with the clinical status of MS patients. There is some suggestion, however, that during quiescence of the disease antibodies may be dominant over MSAA, whereas in an acute phase the reverse seems to be true.
